Nurix Therapeutics, Inc.

NASDAQ:NRIX

Biotechnology

Healthcare
$14.10 +0.85%

+$0.15 today

Market cap
$1.54B
Beta
1.87
P/E (TTM)
-6.4
EPS (TTM)
-$2.68
52W Low $8.20High $22.50

Volume 2.79M

Average 1.74M

NRIX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Nurix Therapeutics, Inc.NASDAQ: NRIX

Gross Margin · Q3 FY2026 · quarter ended Aug 2026

Gross margin widens to 99.7%

Gross margin was 99.7% in Q3 FY2026, up 63.0 pp from a year earlier. On a trailing-twelve-month basis it was 86.5%, up 249.4 pp year over year. Over 3 fiscal years it widened by 455.2 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterAug 2026
99.7%+42.3 pp QoQ
Last fiscal yearNov 2025
77.5%+383.8 pp YoY
LTMAug 2026
86.5%+249.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+63.0 pp——
1 year+383.8 pp——
3 years+455.2 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
77.5%
Year-over-year change
+383.8pp

Gross Margin vs competitors

How NRIX compares with its peers on the latest reported figures

  • NRIX's LTM Aug 2026 gross margin of 86.5% is the lowest of the 7 companies compared; the peer median is 95.6%.
  • Its year-over-year change of +249.4 pp is the highest of 7, against a peer median of +1.9 pp.
  • Over three fiscal years its change of +455.2 pp compares with a peer median of -4.4 pp.
NRIX Competitors Peer median
Gross Margin for NRIX and competitors
Company Period LTM level YoY 3-year change
KYMRKymera Therapeutics, Inc.LTM Jun 2026102.0% +6.6 pp+0.0 pp
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 202698.0% -0.0 pp—
TNGXTango Therapeutics, Inc.FY202596.3% -3.7 pp-3.7 pp
CCCCC4 Therapeutics, Inc.LTM Mar 202694.8% +9.6 pp-22.2 pp
KURAKura Oncology, Inc.LTM Mar 202694.7% -5.0 pp—
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202693.4% +3.7 pp-5.2 pp
NRIXNurix Therapeutics, Inc.LTM Aug 202686.5% +249.4 pp+455.2 pp
RVMDRevolution Medicines, Inc.FY2025— ——
Peer median (excluding NRIX) 95.6%+1.9 pp-4.4 pp

Competitors are the stored peer set for NRIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Nov 2021
FY2022
Nov 2022
FY2023
Nov 2023
FY2024
Nov 2024
FY2025
Nov 2025
Revenue29.75M38.63M76.99M54.55M83.98M
Cost of Revenue116.43M184.5M189.15M221.63M18.86M
Gross Profit(86.68M)(145.87M)(112.16M)(167.08M)65.12M
Gross Margin-291.4%-377.6%-145.7%-306.3%77.5%
Research & Development116.43M184.5M189.15M221.63M308.16M
Selling, General & Admin31.2M38M42.9M45.94M52.74M
Operating Expenses31.2M38M42.9M45.94M350.79M
Depreciation & Amortization6.08M10.81M13.65M16.43M18.86M
EBITDA(110.98M)(169.55M)(130.29M)(176.87M)(244.84M)
EBITDA Margin-373.0%-438.9%-169.2%-324.2%-291.5%
Operating Income(117.89M)(183.87M)(155.06M)(213.03M)(285.67M)
Operating Margin-396.3%-476.0%-201.4%-390.5%-340.2%
Interest Income823K3.51M11.12M19.73M21.97M
Interest Expense00000
Other Income / Expenses823K3.51M11.12M19.73M21.97M
Income Before Tax(117.06M)(180.36M)(143.95M)(193.3M)(263.7M)
Pre-Tax Margin-393.5%-466.9%-187.0%-354.4%-314.0%
Income Tax Expense131K00270K760K
Net Income(117.19M)(180.36M)(143.95M)(193.57M)(264.46M)
Net Margin-393.9%-466.9%-187.0%-354.9%-314.9%
EPS (Basic)(2.73)(3.71)(2.65)(2.88)(3.05)
EPS (Diluted)(2.73)(3.71)(2.65)(2.88)(3.05)
Weighted Avg Shares42.9M48.61M54.34M67.12M86.67M
Weighted Avg Shares (Diluted)42.9M48.61M54.34M67.12M86.67M

Nurix Therapeutics, Inc.

NASDAQ:NRIX

Intrinsic Alpha fair value

Locked

Current Price

$14.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.